Graeme C. Freestone

Graeme C. Freestone

Auto-generated profile, based on publicly available information

Graeme C. Freestone

Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BABrooke A Anderson
Brooke A Anderson
GFGraeme C Freestone
Graeme C Freestone
ALAudrey Low
Audrey Low
CDCheryl L De-Hoyos
Cheryl L De-Hoyos
WIWilliam J Drury Iii
William J Drury Iii
TPThazha Prakash
Thazha Prakash
The PS modification enhances the nuclease stability and protein binding properties of gapmer antisense oligonucleotides (ASOs) and is one of very few modifications that support RNaseH1 activity. We evaluated the effect of introducing stereorandom and chiral mesyl-phosphoramidate (MsPA) linkages in the DNA gap and flanks of gapmer PS ASOs and characterized the effect of these linkages on RNA-binding, nuclease stability, protein binding, pro-inflammatory profile, antisense activity and toxicity in cells and in mice. We show that all PS linkages in a gapmer ASO can be replaced with MsPA without compromising chemical stability and RNA binding affinity but these designs reduced activity. However, replacing up to 5 PS in the gap with MsPA was well tolerated and replacing specific PS linkages at appropriate locations was able to greatly reduce both immune stimulation and cytotoxicity. The improved nuclease stability of MsPA over PS translated to significant improvement in the duration of ASO action in mice which was comparable to that of enhanced stabilized siRNA designs. Our work highlights the combination of PS and MsPA linkages as a next generation chemical platform for identifying ASO drugs with improved potency and therapeutic index, reduced pro-inflammatory effects and extended duration of effect.

1 March 2023 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
TRTamilselvan Rajasekaran
Tamilselvan Rajasekaran
GFGraeme C. Freestone
Graeme C. Freestone
RGRodrigo Galindo-Murillo
Rodrigo Galindo-Murillo
BLBarbara Lugato
Barbara Lugato
HGHans Gaus
Hans Gaus
SHStephen Hanessian
Stephen Hanessian

27 October 2025 in ACS Omega
Verified
Journal Article
Open access
APAlexander Pontarelli
Alexander Pontarelli
GVGuillermo Vasquez
Guillermo Vasquez
WFWuxia Fu
Wuxia Fu
QSQingxia Solan
Qingxia Solan
HGHans J. Gaus
Hans J. Gaus
GFGraeme C. Freestone
Graeme C. Freestone
Enhancing protein translation remains a key objective in the continued development of mRNA-based therapeutics. One promising strategy involves the chemical modification of the 5′ mRNA cap that is essential for RNA stability and translation initiation via eIF4E binding. Given its smaller size, nuclease stability, and unique 3′ → 2′ internucleotide linkage, we evaluated α-l-threofuranosyl nucleic acid (TNA) modification at the 5′-end of mRNA. TNA modified trinucleotide caps were synthesized and incorporated cotranscriptionally into several mRNAs using T7 polymerase with comparable full-length integrity, yield, and capping efficiency relative to reference cap m7G-A OMe G. Capped mRNAs incorporating TNA modification were shown to support translation in cell extract and cultured cells. Placement of TNA at the inverted m7G (m7G TNA -A OMe G) negatively impacted protein translation relative to the predominant natural Cap 1 structure, but notably, TNA modification at the first transcribed nucleotide improved protein production in all evaluated systems. Biochemical experiments suggest that both TNA modified caps improve decapping resistance in vitro and do not significantly increase proinflammatory interleukin-6 release in HeLa cells. In addition, molecular modeling simulations revealed that caps bearing TNA are well accommodated within eIF4E. Lastly, we show that SpCas9 mRNAs containing TNA cap m7G-A TNA G cotransfected with single-guide RNA targeting murine transthyretin (mTtr) resulted in efficient gene editing in cultured cells. These findings contribute to the expanding toolkit of modified cap analogs and further our understanding of the chemical tolerability of specific positions within the cap scaffold.

14 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MNMehran Nikan
Mehran Nikan
TPThazha Prakash
Thazha Prakash
GVGuillermo Vasquez
Guillermo Vasquez
GFGraeme C. Freestone
Graeme C. Freestone
MAMarie Annoual
Marie Annoual
ESEric E. Swayze
Eric E. Swayze
Precise chemical design continues to drive advances in RNA-based therapeutics. Here, we report the synthesis and site-specific incorporation of four canonical phosphoramidites (U, C, A, and G), each bearing non-natural nucleoside configurations: β-D-2′-deoxyxylonucleosides and α-L-2′-deoxyribonucleosides. These stereochemically distinct nucleoside analogs were introduced at positions 6 and 7 within siRNA seed regions. When applied to siRNAs targeting Ttr , ACTN1 , and Marc1 , these modifications reduced off-target gene repression in functional assays and, in several cases, in transcriptome-wide differential expression analyses, while preserving robust on-target activity. In vivo , Marc1 -targeting siRNAs containing these modified nucleosides showed decreased hepatotoxicity, as evidenced by reduced serum ALT and AST levels. Collectively, these findings establish β-D-2′-deoxyxylonucleoside and α-L-2′-deoxyribonucleoside analogs as promising chemical tools for enhancing the specificity and safety of siRNA therapeutics. This work underscores the power of integrating rational nucleoside design with comprehensive functional and in vivo evaluation to advance drug development based on RNA interference (RNAi). GRAPHICAL